A Phase 1 interventional study of APG777 and Placebo in Asthma, sponsored by Apogee Therapeutics, Inc.. Active, not recruiting at 11 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Apogee Therapeutics, Inc. (part of AbbVie) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Asthma by AbbVie — none open to participants now, 1 under way, none of them phase 3. Asthma · AbbVie.
Among the 11 studies in Asthma by AbbVie, this one is the 7th largest by enrollment, is the only one that started in 2025, is one of 3 in phase 1, and was the 11th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 11 studies in Asthma by AbbVie is open now. The open studies under Asthma, anywhere →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 32 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Apogee Therapeutics, Inc., one of the names counted as AbbVie. Under that name alone:
Apogee Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Asthma by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.
The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive protocol specified dose of APG7777
Drug: APG777
Participants will receive matching placebo
Drug: Placebo
APG777 subcutaneous injection
Matching placebo subcutaneous injection
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 52 weeks
Number of Participants with Abnormal Laboratory Findings
Time frame: Up to 52 weeks
Number of Participants with Abnormal Vital Signs
Time frame: Up to 52 weeks
Number of Participants with Abnormal Electrocardiograms (ECGs)
Time frame: Up to 52 weeks
Number of Participants with Abnormal Physical Examination Findings
Time frame: Up to 52 weeks
Maximum concentration (Cmax) of APG777
Time frame: Up to 48 weeks
Time to reach Cmax (tmax)
Time frame: Up to 48 weeks
Terminal elimination rate constant (λz)
Time frame: Up to 48 weeks
Terminal Elimination half-life (t1/2)
Time frame: Up to 48 weeks
Area Under the Serum Concentration-time curve (AUC) from Time 0 to the Last Quantifiable Time Point (AUC0-last)
Time frame: Up to 48 weeks
AUC From Time 0 Extrapolated to Infinity (AUC0-inf)
Time frame: Up to 48 weeks
Apparent Clearance of APG777 (CL/F)
Time frame: Up to 48 weeks
Apparent Volume of Distribution (Vz/F)
Time frame: Up to 48 weeks
Number of Participants with Anti-Drug-Antibodies (ADAs)
Time frame: Up to 48 weeks
Cmax in Participants With and without ADAs
Time frame: Up to 48 weeks
AUClast Participants With and without ADAs
Time frame: Up to 48 weeks
AUCInf Participants With and without ADAs
Time frame: Up to 48 weeks
Ran from Mar 2025 to primary completion in Sep 2026, 17 months.
Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 17 months is above that.
Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zumilokibart